vatalanib has been researched along with sklb1002 in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (sklb1002) | Trials (sklb1002) | Recent Studies (post-2010) (sklb1002) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 6 | 0 | 6 |
| Protein | Taxonomy | vatalanib (IC50) | sklb1002 (IC50) |
|---|---|---|---|
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.032 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brullo, C; Musumeci, F; Radi, M; Schenone, S | 1 |
1 other study(ies) available for vatalanib and sklb1002
| Article | Year |
|---|---|
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Models, Molecular; Neoplasms; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship | 2012 |